8-K current report · filed Oct 16, 2026

Emergent BioSolutions Inc. (EBS) 8-K Current Report: October 16, 2026

Item 5.02Item EX-99.1EBS overview

Short answer

Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on October 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). CFO Richard Lindahl departs December 31, 2026, then advises through March 31, 2027, supporting 2026 Form 10-K preparation.

Emergent BioSolutions Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • CFO Richard Lindahl departs December 31, 2026, then advises through March 31, 2027, supporting 2026 Form 10-K preparation
  • Treasurer Frank Vargo becomes Interim CFO and principal financial and accounting officer January 1, 2027
  • Vargo retains $328,000 base salary plus $3,850 per pay period interim compensation
  • Leadership transition creates near-term execution risk, though internal succession and Lindahl’s advisory period support continuity

Item EX-99.1 · Exhibit EX-99.1

  • CFO Richard S. Lindahl retires December 31, 2026 after nearly nine years at Emergent
  • Treasurer Frank Vargo becomes interim CFO January 1, 2027, signaling internal succession and near-term continuity
  • Lindahl remains senior executive advisor through March 31, 2027, supporting transition and reducing execution risk
  • CFO change occurs during Emergent’s multi-year transformation plan, making financial discipline and strategy continuity key investor watchpoints

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Emergent BioSolutions Inc. 8-K filings

Get the next EBS 8-K as it lands

Follow EBS for push alerts, or ask the research agent what this filing means.